Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule

Drug manufacturer Eli Lilly told HRSA is opposes rescinding a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

Drug manufacturer Eli Lilly,

Read More »

Breaking News

In Surprise Move, Biden Administration Proposes Keeping Trump’s Nearly 30% Cut in 340B Hospitals’ Drug Reimbursement

The U.S. Centers for Medicare & Medicaid Services (CMS) said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Biden administration said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Trump administration implemented the payment reduction in January 2018. Hospital groups say it costs affected 340B hospitals

Read More »

Key Congressional Committee Urges HRSA to Fine Drug Makers Over 340B Contract Pharmacy Denials

U.S. House appropriators are encouraging HRSA to use fines and "any available measures" to hold drug manufacturers accountable for withholding 340B drug discounts.

The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It encouraged

Read More »

House Appropriators Want an Update from HRSA on its Plans to Clarify 340B Patient Definition and Provider Eligibility Criteria, Calls for New GAO Report

House appropriators want GAO to update its pivotal 2011 report on 340B, and want HRSA to report on its plans to implement the report's remaining two recommendations, which focus on clarifying eligibility criteria for 340B patients and providers.

In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.

In its report

Read More »

Law Firm Sues HRSA Over FOIA Request for 340B Contract Pharmacy Documents

Law firm Latham & Watkins says HRSA is impeding its access to records it needs to represent United Therapeutics in its 340B contract pharmacy lawsuit against HRSA and HHS. | Shutterstock

The law firm representing United Therapeutics (UT) in its 340B contract pharmacy lawsuit against the federal government has filed its own related lawsuit against the government.

In a July 13 complaint filed in federal district court in Washington, D.C.,

Read More »

Feds, Novartis, and UT Weigh in on Consolidating 340B Contract Pharmacy Lawsuits

U.S. District Judge Dabney Friedrich is expected to rule soon on whether to consolidate Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

The federal government told a federal district judge yesterday it consents to the judge’s proposal to speed up and simultaneously consider Novartis and United Therapeutics’ (UT) pending motions for preliminary injunctions in the two companies’ 340B contract pharmacy lawsuits. The

Read More »

Lilly Updates its Arguments in 340B Contract Pharmacy Lawsuit

Drug maker Eli Lilly filed a brief in federal district court yesterday refreshing its arguments in its 340B contract pharmacy lawsuit.

Drug manufacturer Eli Lilly yesterday responded to the federal government’s June 25 motion to a federal judge in Indianapolis to dismiss the company’s case challenging the legality and constitutionality of the government’s 340B contract pharmacy requirements and 340B administrative dispute

Read More »

Sixth Drug Manufacturer Sues HHS and HRSA Over 340B Contract Pharmacy

United Therapeutics sued HHS and HRSA on June 23 over 340B contract pharmacy requirements.

Drug manufacturer United Therapeutics (UT) has sued the federal government over its 340B contract pharmacy requirements, saying it is being forced “to engage in a program that enriches national pharmacy corporations at UT’s direct expense and at the expense of

Read More »

Multiple Developments in 340B Contract Pharmacy Lawsuits

Dozens of hospitals in Texas and other states have filed suit against HHS to block a rule that they say lowers their disproportionate share hospital adjustment percentage and could result in a loss of 340B discounts.

Sanofi Slams Government’s Contention of Harm to Covered Entities

Drug maker Sanofi last week updated its lawsuit challenging federal 340B contract pharmacy requirements to poke holes in the government’s introduction of, in the government’s words, “over six thousand pages

Read More »

Biden Gives Becerra 45 Days to Deliver a Plan to Fight Excessive Drug Prices

President Biden has given HHS Secretary Xavier Becerra an Aug. 23 deadline for a plan “to combat excessive pricing of prescription drugs.”

President Biden last Friday gave U.S. Health and Human Services Secretary Xavier Becerra 45 days to deliver a plan “to combat excessive pricing of prescription drugs.” Becerra’s deadline is Aug. 23.

Biden included drug pricing directives in a far-ranging July

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live